Introduction {#sec1}
============

*Corynebacterium diphtheriae* is the etiological agent of a serious infectious disease -- diphtheria. The diphtheria vaccine is highly effective but is directed only against the diphtheria toxin. The non-toxigenic *C. diphtheriae* strains may cause many severe invasive diseases, e.g., endocarditis, septic arthritis, bacteremia, and noninvasive wound infections. The notified increasing number of non-toxigenic *C. diphtheriae* infections indicates that infections are a growing problem in Europe ([@bib2]; [@bib47]; [@bib47]; [@bib12]; [@bib7]). It is hypothesized that high vaccination coverage has resulted in the emergence of non-toxin-producing (non-toxigenic) *C. diphtheriae* strains, which acquired new virulence factors.

The diphtheria toxoid vaccination protects against the action of the toxin but does not protect against colonization and invasion by *C. diphtheriae*. Little is known about *C. diphtheriae* virulence factors other than the diphtheria toxin. The degree of adhesion of microorganisms to host cells has been shown to be an important pathogenicity factor for both toxigenic and non-toxigenic strains ([@bib6]). The virulence factors that facilitate bacterial colonization to specific host tissues and are related to pathogenesis include pili and fimbriae ([@bib32]). These structures are covalently attached to the bacterial cell wall and are recognized by the related host receptors ([@bib35]; [@bib33]). The surface structures are potential candidates for the development of new vaccines and antimicrobial therapies, due to their significant role in pathogenesis ([@bib19]; [@bib38]). Pili are found in both Gram-positive and Gram-negative bacteria, albeit with different folding mechanisms ([@bib40]; [@bib41]). The function of pili is not only the involvement in adhesion, but they also act as bacteriophage receptors and participate in DNA transfer, biofilm formation, cell aggregation, host cell penetration, and motility ([@bib31]).

There are three types of pili in *C. diphtheriae* strains (SpaA, SapD, and SpaH), each containing the LPXTG motif ([@bib42]; [@bib13]; [@bib39]). The genes involved in the production of pili encode nine pili proteins, defined in the successive letters from SpaA to SpaI, and five sortases defined from SrtA to SrtE, which are organized in three separate clusters. The sixth sortase SrtF (class-D homolog) is now referred to as the housekeeping sortase, located in a different region of the chromosome ([@bib42]). *C. diphtheriae*, like other Gram-positive bacteria (e.g. *Streptococcus pneumoniae*, group A and B streptococci or *Actinomycetes*), have the gene encoding cysteine transpeptidase (sortase) conserved in the genome, which is necessary for the assembly of pili ([@bib41]; [@bib22]).

Pili are composed of three proteins: the main subunit forming the stem of pili, and two smaller subunits located at the base and at the end of the pili, e.g., SpaA-type pili is structured in such way that the SpaA pili protein creates a stem, SpaC is located at the end of pili, while SpaB is located along the stem and at the base ([@bib42]; [@bib20]; [@bib33]). SpaA is important for the formation of the pile structure ([@bib41]). It has been proven that in the absence of SpaA protein, SpaB and SpaC are anchored in the cell wall as monomers ([@bib21]).

The adhesion process of *C. diphtheriae* strains to the surface of human cells is multifactorial. Functions and mechanisms of action of fimbriae ([@bib21]), non-fimbrial 67--72p adhesin ([@bib6]), trans-sialidase ([@bib26]), hydrophobins, and sugar residues ([@bib23]; [@bib24]; [@bib27]) are poorly understood, especially how they jointly participate in the adherence to the host cells and in the colonization of these cells during bacterial infection.

Initially, the 67--72p adhesive protein was described as a ligand responsible for the adherence of *C. diphtheriae* to human erythrocytes ([@bib6]). Later, the participation of this protein in the adherence of bacteria to HEp-2 cells was described ([@bib15]). The presence of the 67--72p protein has been confirmed in *C. diphtheriae* strains isolated from various sources, e.g., on the surface of the cells of invasive HC01 strain isolated from the blood of a patient with endocarditis ([@bib34]).

*C. diphtheriae* strains exhibit cell surface hydrophobicity and autoaggregation. Thanks to these features, microorganisms avoid immune defenses and are able to survive on the surface of the skin and mucosal membranes ([@bib25]). In addition, it has been proven that the 67--72p protein has the ability to induce host cell death, giving a signal for apoptosis in the early stages of infection. The occurrence of 67--72p hemagglutinin is one of the characteristics of the potentially invasive strains because it can contribute to the cytotoxicity and apoptosis of the infected cells ([@bib34]).

In our study, we analyzed the nucleotide and amino acid sequences of the genes encoding pili proteins which contribute to bacterial adherence to host cells, and also the gene encoding 67--72p protein involved in adhesion, colonization, and induction of the cell apoptosis in the early stage of infection, which should be used in a preliminary research for the finding of new vaccine antigens.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

**Bacterial strains.** In total, 10 *C. diphtheriae* non-toxigenic isolates were used in this study (Table [I](#tbl1){ref-type="table"}). Strains were isolated in Poland in 2010--2017 from patients with bacteremia, wound infection, septic arthritis, endocarditis, and serous cyst contents. The strain NCTC 13129 was used as the control strain.

###### 

*C. diphtheriae* strains used in this study.

![](pjm-68-2-233-t001)

  Strain   Biotype    Site of isolation       Year of isolation
  -------- ---------- ----------------------- -------------------
  27/E     *mitis*    Serous cyst contents    2010
  40/E     *gravis*   Blood                   2014
  68/E     *gravis*   Endocarditis            2015
  71/E     *gravis*   Wound                   2015
  73/E     *gravis*   Blood                   2016
  77/E     *gravis*   Wound                   2016
  78/E     *gravis*   Blood                   2016
  79/E     *gravis*   Blood and joint fluid   2016
  86/E     *gravis*   Blood                   2017
  89/E     *gravis*   Wound                   2017

**DNA isolation**. *C. diphtheriae* strains were grown on Columbia agar with 5% sheep blood (BioMerieux) for 24 h at 37°C under aerobic conditions. Genomic DNA was isolated using a Wizard Genomic DNA Purification Kit (Promega) according to the Gram-positive bacteria procedure provided by the manufacturer.

**Polymerase Chain Reaction (PCR)**. The oligonucleotide primers for amplification of the genes coding 67--72p protein and structural pili proteins (SpaC, SpaI, SapD) were designed based on the nucleotide sequence of the *C. diphtheriae* NCTC 13129 whole genome, available from GenBank under the number BX248353 (Table [II](#tbl2){ref-type="table"}).

###### 

Table [II](#tbl2){ref-type="table"} Primers used in this study.
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  Gene        Primer                       Sequence                    Length of the amplified fragment
  ----------- ---------------------------- --------------------------- ----------------------------------
  *67--72p*   6772p1L                      TGAAAAATAATTTAAGGAGTTCCAA   695 bp
  6772p1R     CAACCCACCAGTAACAGCAA                                     
  6772p2L     CTGTTTTGCTGGTCGTAGCA         841 bp                      
  6772p2R     ACCTCATCAACCTGGTTTGC                                     
  6772p3L     GAATCGTTGCAGCCCAAG           699 bp                      
  6772p3R     CCTTAAGCACTGGGTCGTTT                                     
  6772p4L     CACCGACAACGTTGGTTACA         844 bp                      
  6772p4R     TTCTGGCTTGTCCCTGTTCT                                     
  6772p5L     TCAAGCCGGAGTCCCAGA           692 bp                      
  6772p5R     TCAGTTGTGTCTGGTGAAAGG                                    
  *spaI*      SpaI1L                       GCGGAATCAACACCAACAC         600 bp
  SpaI1R      AAGCGCTTACGATCCAAGAA                                     
  SpaI2L      ACACGGCCTTCCAAACTTC          482 bp                      
  SpaI2R      TGATATTGAGGCGTCGCTAA                                     
  *sapD*      SapD1L                       TCGCGAAGGTAAGAAATACTCA      698 bp
  SapD1R      CGTTTGTATCCGAGCCACTT                                     
  SapD2L      GTCCAAAACAAGAGCGGAAA         814 bp                      
  SapD2R      GGTTCAGTGAAAACCCAGTTG                                    
  *spaC*      SpaC1L                       GCCTACTCTCACTGGCAAGG        824 bp
  SpaC1R      ACATGGCGATCTCCTGAAGT                                     
  SpaC2L      TCGTGCAGGACGTACCAATA         838 bp                      
  SpaC2R      AACTGCACTGTGACCGAAAA                                     
  SpaC3L      GGCATCATAAAGTGCAATCG         808 bp                      
  SpaC3R      TCACGTTGAGTTCTTCGTTCA                                    
  SpaC4L      CATTCGTTTTTGTTCCGTGA         850 bp                      
  SpaC4R      GGTGTAGAAACGCCTCGAAA                                     
  SpaC5L      CCAAATTCAACAGTTTGATTATCACT   850 bp                      
  SpaC5R      TTCCTGTCACTTACACCTGTCG                                   
  SpaC6L      CAAAATACGGATTGGTTTCTGG       845 bp                      
  SpaC6R      AGCTGGCTGGAATTTCGAT                                      
  SpaC7L      CAAAGGTGTCTTGGCCATTT         687 bp                      
  SpaC7R      TCACGCCAGTAAGTCTTGCTAA                                   
  SpaC8L      CTGGCATCTGGATGTCATTG         578 bp                      
  SpaC8R      ACCGAACGTGCCTAGCGTA                                      

The PCR reaction was conducted in a total volume of 25 μl and the reaction mixture contained 0.5 μl genomic DNA, 12.5 μl HotStarTaq Master Mix (Qiagen), and 1 μl of 10 μM solution of each primer (Table [II](#tbl2){ref-type="table"}). The cycling conditions were as follows: initial denaturation at 95°C/10 min and 29 cycles of denaturation at 94°C/1 min, primer annealing at 52°C/45 s, primer extension at 72°C/1 min and a final elongation at 72°C/10 min.

The PCR products were enzymatically cleaned using an Exo-BAP Mix kit (EURx), according to the manufacturer's procedure and then sent for sequencing.

**Sequencing of fragment 4 of the gene encoding SpaC protein in strain 89/E.** Based on the result of the first round of sequencing, new primers were designed to completely sequence a fragment of approximately 2000 bp, as follows: SpaC4L 5'-CATTCGTTTTTGTT CCGTGA-3' and SC1pR 5'-GAGCTGCTTGAAGTT GCAGA-3' (391 bp), SC2pL 5'-CCCGAACACGTTTG GTAAGT-3' and SC2pR 5'-GGGTAGTGGGTCAGGG TTTT-3' (687 bp), SC3pL 5'-CGCACACAATCAGTGA CTAAAA-3' and SC3pR 5'-ACAACGTATTCGCAGCA GTG-3' (850 bp), SC4pL 5'-ATGGTTATCGCCGTATC TGG-3' and SpaC4R 5'-GGTGTAGAAACGCCTCGA AA-3' (764 bp). The PCR reaction was carried out according to the above conditions, the PCR products were then enzymatically purified and sent for sequencing.

**Comparing the sequenced fragments and the translated nucleotide sequences for proteins.** The sequences of the particular gene fragments were obtained as fluorograms. The BioEdit program was used for the gene assembly, alignment of sequences and comparative calculations. The translation of DNA into protein sequences was performed using the BLASTx program.

**Analysis of 67--72p, SpaC, SpaI and SapD protein affinity to MHC classes I and II and linear epitopes.** Amino acid sequences of *C. diphtheriae* NCTC 13129 reference strain available from the National Center for Biotechnology Information (NCBI) were used for analysis. To predict the cellular localization of the proteins, the software packages CELLO v.2.5 ([@bib44]) and PSORTb version 3.0.2 ([@bib45]) were used. The analysis for the transmembrane domains was performed using TMHMM Server v. 2.0. The MHC classes I and II binding prediction was performed using the immune epitope database (IEDB) ([@bib18]) for the recommended human leukocyte antigen (HLA) allele set ([@bib3]; [@bib29]). Analysis has also been carried out using Propred-I (for MHC class I) and Propred (for MHC class II) regarding the number of alleles for which epitopes were found in the proteins analyzed ([@bib37]; [@bib36]). The prediction of linear B-cell epitopes has been carried out using the Bepipred Linear Epitope Prediction 2.0 ([@bib17]). VaxiJen 2.0 was used for prediction of the protective antigens. The results page on VaxiJen server creates lists of the selected target, the protein sequence, its prediction probability, and a statement of protective antigen or non-antigen, according to a predefined cut-off. Since more of the models had their highest accuracy at a threshold of 0.5, this threshold value was chosen for all bacterial models types ([@bib8]).

Results {#sec4}
=======

The isolates from invasive diseases and wound infections were included in the study because a wound can be a portal of entry for invasive infections. Moreover, future vaccines against non-toxigenic *C. diphtheriae* should protect against all kinds of infections. The analyses conducted in this study showed the variability of *C. diphtheriae* strains in terms of the nucleotide sequence of the genes encoding the 67--72p protein (99.37--100% average similarity) and structural proteins of pili SpaC (38.94--99.97% average similarity), SpaI (81.39--100% average similarity), and SapD (63.78--100% average similarity). The 27/E strain, the only representative of the *mitis* biotype, was the most different from the other strains tested. This strain did not have the gene coding for the SpaI protein, while the average similarities of the nucleotide sequence of genes encoding the 67--72p, SapD, and SpaC proteins were 99.37%, 98.64%, and 38.94%, respectively when compared to the reference strain. Despite the significant variation, we managed to locate two fragments of the 67--72p protein (fragments No. 3 and 5), where the nucleotide sequences were 100% identical for all *C. diphtheriae* strains tested (the most conserved in the genome). In contrast, for *C. diphtheriae* biotype *gravis* we found as many as nine fragments located in the sequence of the gene encoding 67--72p protein (fragment No. 1, 3, 5) and the genes coding for the pili SapD (fragment No. 1), SpaI (fragment No. 2), and SpaC (fragment No. 2, 3, 7, 8), which were 100% identical in all nine strains tested (Table [III](#tbl3){ref-type="table"}).

###### 

Comparison of the nucleotide sequences of all strains tested against the reference strain, given in percent (%). The sequences are presented according to the analysed fragments.
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  Target protein   Fragment   27E     40E     68E     71E     73E     77E     78E     79E     86E                                    89E
  ---------------- ---------- ------- ------- ------- ------- ------- ------- ------- ------- -------------------------------------- -------
  67--72p          1          98.35   100     100     100     100     100     100     100     100                                    100
  2                99.5       100     100     100     100     100     100     100     100     99.87                                  
  3                100        100     100     100     100     100     100     100     100     100                                    
  4                99.01      100     100     100     100     100     100     100     97.90   97.90                                  
  5                100        100     100     100     100     100     100     100     100     100                                    
  SapD             1          98.91   100     100     100     100     100     100     100     100                                    100
  2                98.37      27.52   100     100     100     100     100     100     99.86   99.86                                  
  SpaI             1          −       100     100     100     100     100     100     62.77   100                                    100
  2                −          100     100     100     100     100     100     100     100     100                                    
  SpaC             1          72.78   99.87   99.87   99.87   99.87   99.87   99.87   99.87   99.87                                  99.87
  2                97.11      100     100     100     100     100     100     100     100     100                                    
  3                −          100     100     100     100     100     100     100     100     100                                    
  4                −          100     100     100     100     100     100     100     99.75   IS^[\*](#FNt3){ref-type="table-fn"}^   
  5                91.47      99.21   100     100     99.87   100     100     100     100     100                                    
  6                −          100     100     100     100     100     99.87   99.87   100     100                                    
  7                50.16      100     100     100     100     100     100     100     100     100                                    
  8                −          100     100     100     100     100     100     100     100     100                                    

In the fragment 4 of the gene encoding SpaC protein, the insertion sequence has been transposed

The nucleotide sequences of the genes investigated were translated into the amino acid sequences. We revealed that the identified mutations resulted in a reading frame shift or were synonymous and nonsynonymous substitutions (Table [IV](#tbl4){ref-type="table"}).

###### 

Comparison of amino acid sequences of all strains tested against the reference strain, given in percent (%).
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  Target protein   27E   40E   68E   71E   73E   77E   78E   79E   86E   89E
  ---------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  67--72p          99    100   100   100   100   100   100   98    98    100
  SapD             97    99    100   100   100   100   100   100   99    99
  SpaI             −     100   100   100   100   100   100   84    100   100
  SpaC             48    99    99    99    69    99    69    69    69    51

In addition, we observed that a fragment of 1380 bp was inserted in the place of the gene encoding the SpaC protein in the 89/E strain (Table [III](#tbl3){ref-type="table"}). After sequencing the fragment No. 4 of *spaC*, we obtained the exact nucleotide sequence, which we compared to the available sequences in the GeneBank using the Nucleotide Basic Local Alignment Search Tool (BLASTn). In this way, we proved that the 1380 bp insertion sequence (IS) was transposed, which interrupted the continuity of the tested gene between 3072 bp and 3073 bp of the reference sequence of the NCTC 13129 strain. The result from the BLAST search revealed that the insertion fragment we detected was similar to the sequence of IS3 family transposase also identified in other *C. diphtheriae* strains but in different locations.

Analysis of the 67--72p, SpaC, SpaI and SapD protein affinity to MHC classes I and II, and linear B-cell epitopes in the first stage relied on the determination of the position of the proteins tested in the cell membrane and confirmation that all selected proteins were at least partially membranous or extracellular (Table [V](#tbl5){ref-type="table"}). Then, using the IEDB platform, it was observed that all proteins have high-affinity areas for MHC receptors of both classes and the fragments, which can be recognized by antibodies. The output for the prediction of the high- affinity MHC binding peptides is typically given either in the units of a predicted affinity (IC~50~ nanomolar) or as a percentile score reflecting the relative affinity of a selected peptide compared with a universe of random sequences. According to [@bib30], there are four categories of percentile ranks: 1) 0--0.30; 2) 0.30--1.25; 3) 1.25--5.0; and 4) 5.0--15.0. Their study proved that four pools of predicted peptides derived from the first two categories (0--0.30; 0.30--1.25) were immunogenic but finally, the transgenic mice in their study recognized only one peptide pool from the first category (0--0.30) ([@bib30]). We can say that the smaller the percentile rank value, the higher the affinity. As for the IC~50~ value, according to the IEDB Solutions Centre guidelines, IC~50~ \< 50 designs very high affinity, IC~50~ \< 500 -- high affinity, and IC~50~ \< 5000 means low affinity (Fleri 2013). Accepting even the threshold of cutting off the percentile rank below 1 or IC~50~ below 50, we still could have at least 100 to several hundred regions with high affinity for each of the proteins (Table [VI](#tbl6){ref-type="table"}, Table [VII](#tbl7){ref-type="table"}).

###### 

Extracellular regions of individual proteins.
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  Region^[\*](#FNt4){ref-type="table-fn"}^   67--72p   SpaC   SpaI   SapD
  ------------------------------------------ --------- ------ ------ ------
  Start                                      44        138    235    310
  Stop                                       57        169    257    987

Amino acid positions

###### 

MHC class I epitopes predicted from the target proteins.
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  MHC I                                                 
  --------- ---------------- ------ ------ ------------ ------
  67--72p   HLA-A^\*^02:06   6      14     FTNDRFWSV    0.06
  67--72p   HLA-B^\*^44:02   34     42     SENDSSVEY    0.06
  67--72p   HLA-A^\*^30:02   68     77     RMASYWLDRY   0.06
  67--72p   HLA-B^\*^44:02   9      17     AEALSQVGI    0.07
  67--72p   HLA-A^\*^02:06   27     36     MILGALVPTV   0.07
  67--72p   HLA-A^\*^68:01   1      9      YAFTLPALR    0.11
  67--72p   HLA-A^\*^01:01   43     51     DTDSSTYTY    0.11
  67--72p   HLA-A^\*^01:01   48     56     YTTLTSLPY    0.11
  67--72p   HLA-B^\*^44:03   34     42     SENDSSVEY    0.11
  67--72p   HLA-B^\*^57:01   58     66     SSLAIGNAW    0.12
  SapD      HLA-B^\*^44:03   65     74     AEWQELDTWW   0.06
  SapD      HLA-B^\*^07:02   4      13     RPIWAGIGAF   0.11
  SapD      HLA-B^\*^44:03   28     36     KEGAYGLEY    0.11
  SapD      HLA-A^\*^68:01   47     55     NVFFKNNSR    0.12
  SapD      HLA-B^\*^40:01   10     18     IEAQISGSL    0.17
  SapD      HLA-A^\*^24:02   70     79     VWYAPQNIPF   0.18
  SapD      HLA-A^\*^68:01   24     32     DTVGSESAR    0.2
  SapD      HLA-B^\*^51:01   50     58     YPLHISYLV    0.2
  SapD      HLA-A^\*^68:01   41     50     EPAFGVTIPK   0.22
  SapD      HLA-A^\*^68:01   17     26     EAYVKNGAFK   0.26
  SpaC      HLA-A^\*^11:01   658    666    STNSVWIPK    0.06
  SpaC      HLA-A^\*^01:01   220    229    LSDDKPFDLY   0.07
  SpaC      HLA-B^\*^53:01   233    241    LPSEDDYYW    0.1
  SpaC      HLA-A^\*^68:02   191    199    EVVELENAV    0.1
  SpaC      HLA-A^\*^02:06   1859   1867   LVAAALWLV    0.11
  SpaC      HLA-A^\*^23:01   88     96     PYRFGIYTF    0.11
  SpaC      HLA-A^\*^68:01   1436   1444   NTTYSITYK    0.11
  SpaC      HLA-A^\*^31:01   363    371    RFKNARCQR    0.11
  SpaC      HLA-B^\*^44:02   1054   1063   AENTLSADAI   0.11
  SpaC      HLA-A^\*^23:01   1578   1587   SYTCTMPHLF   0.12
  SpaI      HLA-A^\*^30:01   2      11     KKTHLFRIPA   0.08
  SpaI      HLA-B^\*^07:02   9      17     IPAATTAAV    0.1
  SpaI      HLA-B^\*^07:02   147    155    RPAEYRRTL    0.1
  SpaI      HLA-B^\*^57:01   109    117    RSRLSDEVW    0.12
  SpaI      HLA-A^\*^30:02   129    137    VTGLPMGVY    0.18
  SpaI      HLA-A^\*^02:01   137    145    YLVSETPPA    0.2
  SpaI      HLA-A^\*^02:03   20     29     LLASGPIASA   0.2
  SpaI      HLA-A^\*^02:06   153    161    RTLDFLITV    0.21
  SpaI      HLA-B^\*^51:01   196    205    FPPVESSVTL   0.24
  SpaI      HLA-A^\*^68:01   252    261    LAIAGFLVQR   0.32

###### 

MHC class II epitopes predicted from the target proteins.
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  MHC II                                                                      
  --------- --------------------------------- ------ ------ ----------------- ------
  67--72p   HLA-DRB3^\*^01:01                 660    674    DGSVDLYEFDENDPV   0.01
  67--72p   HLA-DRB3^\*^01:01                 713    727    MLARYHVDDARDFFT   0.01
  67--72p   HLA-DPA1^\*^03:01/DPB1^\*^04:02   15     29     PQRRLTWLIPLLMIL   0.01
  67--72p   HLA-DPA1^\*^03:01/DPB1^\*^04:02   173    187    STFSVLLVVAFLIAL   0.01
  67--72p   HLA-DRB1^\*^07:01                 49     63     VDFRGVFNKVIATRI   0.01
  67--72p   HLA-DPA1^\*^01/DPB1^\*^04:01      165    179    LPALRLVVSTFSVLL   0.01
  67--72p   HLA-DPA1^\*^01/DPB1^\*^04:01      267    281    VISAVVAISFFSVIV   0.01
  67--72p   HLA-DRB1^\*^09:01                 100    114    PVVQYRAAVEKGVHR   0.02
  67--72p   HLA-DRB3^\*^01:01                 712    726    KMLARYHVDDARDFF   0.02
  67--72p   HLA-DPA1^\*^01:03/DPB1^\*^02:01   172    186    VSTFSVLLVVAFLIA   0.02
  SapD      HLA-DRB3^\*^01:01                 181    195    GKDSIPEHLDKNMYF   0.01
  SapD      HLA-DRB1^\*^03:01                 531    545    PLHISYLVGDATIAR   0.03
  SapD      HLA-DQA1^\*^04:01/DQB1^\*^04:02   535    549    SYLVGDATIARAKEI   0.09
  SapD      HLA-DRB1^\*^03:01                 444    458    PSDALLPDSKMTVSL   0.12
  SapD      HLA-DQA1^\*^03:01/DQB1^\*^03:02   616    630    VQDEAVTTAAEWQEL   0.13
  SapD      HLA-DRB1^\*^03:01                 442    456    DLPSDALLPDSKMTV   0.13
  SapD      HLA-DQA1^\*^03:01/DQB1^\*^03:02   615    629    DVQDEAVTTAAEWQE   0.16
  SapD      HLA-DRB5^\*^01:01                 640    654    LLGILGIVGAFVLFR   0.24
  SapD      HLA-DQA1^\*^04:01/DQB1^\*^04:02   537    551    LVGDATIARAKEILA   0.27
  SapD      HLA-DRB1^\*^03:01                 346    360    TGTPKTIINDGHMDL   0.29
  SpaC      HLA-DRB3^\*^01:01                 157    171    NDIDRGIKYDAVYFI   0.01
  SpaC      HLA-DRB3^\*^01:01                 505    519    DNGTYRFKADTDAFK   0.01
  SpaC      HLA-DRB3^\*^01:01                 1427   1441   EHSVDPWLLNTTYSI   0.01
  SpaC      HLA-DRB3^\*^01:01                 1699   1713   VVINNVYTTDAEINI   0.01
  SpaC      HLA-DRB3^\*^01:01                 1804   1818   EVTLDNYDADSGLIT   0.01
  SpaC      HLA-DRB3^\*^01:01                 1450   1464   IKDRSYSNDVDIQAD   0.02
  SpaC      HLA-DRB1^\*^03:01                 769    783    AGDIVKVVVDNTAKR   0.03
  SpaC      HLA-DRB1^\*^09:01                 1845   1859   NGYLRWLLAGAAGLL   0.04
  SpaC      HLA-DPA1^\*^03:01/DPB1^\*^04:02   21     35     LAMVMSIVLVPLIAA   0.05
  SpaC      HLA-DRB3^\*^01:01                 1432   1446   PWLLNTTYSITYKCD   0.07
  SpaI      HLA-DRB3^\*^01:01                 147    161    RPAEYRRTLDFLITV   0.07
  SpaI      HLA-DRB1^\*^08:02                 3      17     KTHLFRIPAATTAAV   0.18
  SpaI      HLA-DRB3^\*^01:01                 151    165    YRRTLDFLITVPAGM   0.19
  SpaI      HLA-DPA1^\*^01/DPB1^\*^04:01      248    262    LGIALAIAGFLVQRR   0.28
  SpaI      HLA-DRB3^\*^01:01                 43     57     ISDIRCDTGSLTLIK   0.29
  SpaI      HLA-DRB5^\*^01:01                 155    169    LDFLITVPAGMRTAD   0.42
  SpaI      HLA-DRB1^\*^09:01                 95     109    AGWDAAKALTIQEAR   0.44
  SpaI      HLA-DRB1^\*^11:01                 50     64     TGSLTLIKRPPAAFE   0.44
  SpaI      HLA-DQA1^\*^01:02/DQB1^\*^06:02   242    256    VLGIAALGIALAIAG   0.48
  SpaI      HLA-DPA1^\*^02:01/DPB1^\*^05:01   150    164    EYRRTLDFLITVPAG   0.6

Table [VIII](#tbl8){ref-type="table"} contains data on the number of alleles for which epitope that was found in the proteins analyzed. Overall, 40 HLA alleles of human origin encoded by HLA-A and HLA-B were selected for ProPred1. The HLA 7 from mouse s-derived (MHC-Db, MHC-Db revised, MHC-Dd, MHC-Kb, MHC-Kd, MHC-Kk, and MHC-Ld) was omitted. The Proteasome Filter and Immunoproteasome filters were included in the analysis and for both, the threshold score of 4% was used. The ProPred1 cut-off threshold was also set at 4%. At the ProPred, 51 alleles related to MHC class II were considered. These were HLA-DR alleles. These molecules were encoded by DRB1 and DRB5 genes containing HLA DR1 (2 alleles), DR3 (7 alleles), DR4 (9 alleles), DR7 (2 alleles), DR8 (6 alleles), DR11 (9 alleles), DR13 (11 alleles), DR15 (3 alleles), and DR51 (2 alleles). The cut-off threshold was set at 3%.

###### 

Number of alleles for which epitopes were found in the proteins tested.

![](pjm-68-2-233-t008)

  Target protein   Number of MHC alleles of class I (per 40)   \% Bound alleles MHC class I   Number of MHC alleles of class II (per 51)   \% Bound alleles MHC class II
  ---------------- ------------------------------------------- ------------------------------ -------------------------------------------- -------------------------------
  67--72p          40                                          100                            51                                           100
  SpaC             37                                          92.5                           51                                           100
  SpaI             34                                          85                             50                                           98
  SapD             33                                          82.5                           51                                           100

The target protein sequences were scanned for B-cell epitopes using the Bepipred Linear Epitope Prediction 2.0. The selected B-cell linear epitopes of the proteins analyzed are shown in Table [IX](#tbl9){ref-type="table"}.

###### 

B-cell epitopes predicted from the target proteins.
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  Target protein   No.   Start   End    Peptide                                                                   Length
  ---------------- ----- ------- ------ ------------------------------------------------------------------------- --------
  6772p            1     4       20     GFTRPAAAPKRPQRRLT                                                         17
  6772p            2     48      53     EVDFRG                                                                    6
  6772p            3     87      111    GRPDELEFFDPDSPVVQYRAAVEKG                                                 25
  6772p            4     143     156    NRQDFGVSDQQFGM                                                            14
  6772p            5     194     211    GGIRAGNQAAGVKGSITN                                                        18
  6772p            6     281     287    VTKDLRI                                                                   7
  6772p            7     316     329    SPNRAEKESEYISR                                                            14
  6772p            8     337     369    AYGITDDAVTYKDNWGAKGASSEKVASDSATVS                                         33
  6772p            9     381     410    PTFTQQQQLRNFYGFPKSLAMDRYVIDGEL                                            30
  6772p            10    421     434    DPNALKENQRDWIN                                                            14
  6772p            11    452     467    QVDEVARDVGSARGGY                                                          16
  6772p            12    474     490    DLQTTDKEAQELGIVVK                                                         17
  6772p            13    498     507    PVIASATDGA                                                                10
  6772p            14    514     541    SENDSSVEYDTDSSTYTYQGKGGVNIGN                                              28
  6772p            15    562     566    RVNGN                                                                     5
  6772p            16    573     581    RDPRERVHN                                                                 9
  6772p            17    612     645    TSLPYAERTSLSEATNDTTAQVGNSAQRLVTDNV                                        34
  6772p            18    680     705    GVFPGTVKAKSEISEELMNHLRYPED                                                26
  6772p            19    714     749    LARYHVDDARDFFTNDRFWSVPSDPSATEGQKDVAQ                                      36
  6772p            20    760     763    DTGK                                                                      4
  6772p            21    773     777    RGLQR                                                                     5
  6772p            22    803     837    TDTLTQGPKQAQDTMMSSDQIASDRTLWKDTNDLF                                       35
  6772p            23    861     868    RKNQASAF                                                                  8
  6772p            24    896     944    GIDPKEAQDLGEAKGLKPESQNRDKPEDKEGKAPSTPSAPASGSGTTGE                         49
  6772p            25    956     976    LQSAKNGSNEEYGRALDELDK                                                     21
  SpaC             1     38      49     ANAEPLPKKEFE                                                              12
  SpaC             2     64      69     SLSASD                                                                    6
  SpaC             3     100     113    SPAAGNKNFTPVSL                                                            14
  SpaC             4     131     146    MPAIRENKKGSPNGGT                                                          16
  SpaC             5     176     184    PTWDNNGRN                                                                 9
  SpaC             6     225     228    PFDL                                                                      4
  SpaC             7     231     234    PILP                                                                      4
  SpaC             8     246     254    WKIDRSLTG                                                                 9
  SpaC             9     324     332    PSIETDKNG                                                                 9
  SpaC             10    355     358    TGDQ                                                                      4
  SpaC             11    371     387    RYSYGQAPTDIPIKTSD                                                         17
  SpaC             12    417     432    KVNVNTPQLLEELNNQ                                                          16
  SpaC             13    455     468    GVHNGESKEIGKVA                                                            14
  SpaC             14    478     507    VTPKVDDSRMKLSTTWSSENTTADANQDNG                                            30
  SpaC             15    512     522    KADTDAFKNKK                                                               11
  SpaC             16    531     537    NYEAQTA                                                                   7
  SpaC             17    545     561    IINRDKIPATKLPEKFP                                                         17
  SpaC             18    569     591    VPHPNARPEHGGLPETNPYFVDS                                                   23
  SpaC             19    601     610    SIEIGPFPVG                                                                10
  SpaC             20    619     659    ARLDPNVQADAKIPGFSLKTEWNSNICFGNTIDNNSQDCST                                 41
  SpaC             21    664     672    IPKPGQYSL                                                                 9
  SpaC             22    676     684    NTYTRELAS                                                                 9
  SpaC             23    690     702    TVSGDASDLTNSH                                                             13
  SpaC             24    712     731    DSGVEVYSQDNIVVKKDGRQ                                                      20
  SpaC             25    746     754    EKQPEQKGV                                                                 9
  SpaC             26    761     769    PFHLRASTA                                                                 9
  SpaC             27    779     786    NTAKRQVA                                                                  8
  SpaC             28    792     812    KKVHKKDTFSPEISASIDALT                                                     21
  SpaC             29    819     846    CTVPGVETPRKVLKTVSDNQTVEFGNFP                                              28
  SpaC             30    857     861    TEAPA                                                                     5
  SpaC             31    881     885    TPINK                                                                     5
  SpaC             32    891     895    FENAR                                                                     5
  SpaC             33    904     948    VLDGDMPQALVDQIPSSFTVNVACSITGNHSITLQKDEQKAVPGV                             45
  SpaC             34    957     968    SEEVTPITGATH                                                              12
  SpaC             35    971     991    HWIKGELLEVADSTDITINPN                                                     21
  SpaC             36    1001    1007   HYETDAV                                                                   7
  SpaC             37    1012    1037   TKRVRVIDQVGNDVNSELKNAVVRPE                                                26
  SpaC             38    1043    1052   RYRCEINGQV                                                                10
  SpaC             39    1059    1073   SADAINTGATKVPRG                                                           15
  SpaC             40    1079    1131   EEDSSSVELSNATLSHVEFFVHGTKTNDKASVAINSDHNRLDATNTFTLKTGS                     53
  SpaC             41    1135    1146   KKKVDGEGVSTI                                                              12
  SpaC             42    1157    1164   RCTLGDWK                                                                  8
  SpaC             43    1174    1188   FDSAESHSVKDIPVG                                                           15
  SpaC             44    1195    1204   EDSEKAQEPN                                                                10
  SpaC             45    1210    1240   RWTHTDSTNGWGDTEAACENHAACEVDPKNE                                           31
  SpaC             46    1250    1255   NEKENF                                                                    6
  SpaC             47    1276    1288   KVLTNDGPELAGK                                                             13
  SpaC             48    1298    1346   TDPRFAGSDLADKHSIPDPTITVALNAKGQSRASYQVADERHDSVEVPV                         49
  SpaC             49    1357    1360   IALY                                                                      4
  SpaC             50    1378    1401   AVQRTSSNSASARFVTEKQENNGT                                                  24
  SpaC             51    1409    1413   DYIRP                                                                     5
  SpaC             52    1424    1437   AKPEHSVDPWLLNT                                                            14
  SpaC             53    1443    1483   YKCDDPYIKDRSYSNDVDIQADAEKPTPIFADPTAHVKIPA                                 41
  SpaC             54    1492    1498   NTEGHLP                                                                   7
  SpaC             55    1506    1555   DETNKVAEFAGEHEKRSYFTPEIKDVVLSESEPTRIEFTNSYVMPQRILS                        50
  SpaC             56    1560    1569   VEGDPGHAVI                                                                10
  SpaC             57    1582    1605   TMPHLFPNQPNPMSQEVGNKVARG                                                  24
  SpaC             58    1614    1622   TWRSPEVPI                                                                 9
  SpaC             59    1630    1643   EEDDPALRTKLENN                                                            14
  SpaC             60    1645    1687   LRMVPTYLFPTERAGAASAPVIPPLTDRPIYNGTEPRLQMPES                               43
  SpaC             61    1718    1723   ADNSPL                                                                    6
  SpaC             62    1734    1755   GENGQRKELPEVADAPAKSAKS                                                    22
  SpaC             63    1808    1825   DNYDADSGLITVEHPQGK                                                        18
  SpaC             64    1837    1842   STLPLT                                                                    6
  SapD             1     23      72     PVSASEDAALDATGHKKGEPAFGVTIPKGTTYRDSDGKEVPHPCVDRKIG                        50
  SapD             2     86      96     YSVKEPATDLP                                                               11
  SapD             3     104     113    DGQQVVPQES                                                                10
  SapD             4     122     145    AGEDGEELSRIRIPDDEEFSFLGK                                                  24
  SapD             5     157     162    IPFANG                                                                    6
  SapD             6     174     190    DPHHEPKGKDSIPEHLD                                                         17
  SapD             7     224     234    SNDEELKTIEY                                                               11
  SapD             8     264     269    AFKVKT                                                                    6
  SapD             9     281     350    DEEVGLPEGTTTNLNKITKPLDKDATNEPPTDPSEKKKPPRPEKGHSETSSPSA LDDSIERAWKLTGTPK   70
  SapD             10    371     380    TVINREGKKY                                                                10
  SapD             11    392     418    SGGDQGGPLVKTDSWKDRIEAQISGSL                                               27
  SapD             12    441     451    EDLPSDALLPD                                                               11
  SapD             13    525     529    GKQES                                                                     5
  SapD             14    542     606    TIARAKEILAGEKLGGSLKKKPQEKETKKPASVQNKSGKHNKDTVGSESARK RQQLAATSGSDTN        65
  SapD             15    624     632    AAEWQELDT                                                                 9
  SpaI             1     22      50     ASGPIASADSRTITGATDGLNISDIRCDT                                             29
  SpaI             2     55      75     LIKRPPAAFEGVDKADLPAGT                                                     21
  SpaI             3     86      124    IEGIDLTKQAGWDAAKALTIQEARSRLSDEVWKAVSGRD                                   39
  SpaI             4     144     153    PAKRPAEYRR                                                                10
  SpaI             5     166     174    RTADGNVAS                                                                 9
  SpaI             6     186     242    TDDLPPTVPVFPPVESSVTLTPSSPVPGTPKTPGKPDLPEKFRKEVTDRLGNT GANV                57
  SpaI             7     263     266    KKNE                                                                      4

The results obtained with the VaxiJen server also confirmed the possibility of using the proteins as antigens in vaccines (Table [X](#tbl10){ref-type="table"}).

###### 

Prediction of the protective antigens from the VaxiJen server.

![](pjm-68-2-233-t010)

  Protein   Overall Prediction for the Antigen
  --------- ------------------------------------
  6772p     0.5123
  SpaC      0.6757
  SpaI      0.5504
  SapD      0.5544

Discussion {#sec5}
==========

The huge success of vaccination against diphtheria almost enabled the elimination of the disease in Europe and other developed countries. However, in many countries with high vaccination coverage, i.e. France, Italy, Switzerland, Germany, and Canada an increase in non-toxigenic *C. diphtheriae* infections has been observed. For example, Poland is a country where the last case of diphtheria was recorded in the year 2000 and where the vaccination level of over 95% is achieved ([@bib47]). The first case of non-toxigenic infection with *C. diphtheriae* biotype *gravis* was recorded in Poland in 2004, where this bacterium induced sepsis and endocarditis in a patient ([@bib46]) and since then, practically every year, several cases of invasive *C. diphtheriae* infections have been diagnosed. In northern Germany, the number of non-toxigenic *C. diphtheriae* infections increased from five in 2013 to 23 in 2016, and 24 in only the first half of 2017 ([@bib7]). In England and Wales, a dramatic increase in infections was recorded since 1986, peaking at almost 300 cases in the year 2000 ([@bib10]). These examples indicate that the development of a new vaccine against non-toxigenic *C. diphtheriae* infection is of very important and necessary demand.

In vaccine development, the potential virulence factors exposed on the surface of a pathogen are considered as suitable antigens for an effective acellular vaccine. It has been shown that pili of Gram-positive bacteria play a direct role in the pathogenesis. For example, studies on *S. pneumoniae* have proved that those strains, which have a pili island, adhere better to lung epithelial cells than do the strains that lack this island. In the invasive disease model, the piliated strain is more virulent and has a competitive advantage over the pili-negative strain after the mixed intranasal infection. Infection with the piliated strain induces a stronger inflammatory response and a higher level of the tumor necrosis factor in the bloodstream of mice, which may be due to the higher adhesion of the piliated bacteria to the cells involved in the innate immune response and their detection by host cell pattern-recognition receptors ([@bib1]). The pili proteins are used as antigens in vaccines, for example in some acellular pertussis vaccines ([@bib28]).

The adhesion of *Corynebacterium* to host cells was observed for the first time for *C. renale* pili, which caused agglutination of trypsinized sheep red blood cells (Honda and Yanagawa 1974). It was not until more than thirty years later that Mandlik and colleagues identified adhesins, which were involved in adherence to pharyngeal host cells -- the minor pilins SpaB and SpaC of *C. diphtheriae* ([@bib21]). Subsequent studies showed that wild type *C. diphtheriae* cells bind to human lung epithelial, laryngeal, and pharyngeal cells, whereas mutants that lacked SrtA (i.e. they did not polymerize the SpaA-type pili) showed more than a 90% lower ability to adhere to human pharyngeal cells. Moreover, mutants that lacked only the major pili subunit, SpaA, showed a 10% reduction in adherence to these cells. In contrast, mutants that lacked either of the minor pilin subunits, SpaB or SpaC, showed a 70--75% reduction in adhesion. In addition, the latex beads coated only with SpaB or SpaC were sufficient to adhere to the host pharyngeal cells, while the SpaA-coated beads did not bind. SpaB and SpaC are anchored in the cell wall as monomers independent of the pilus structures. It is likely that the long pili mediate the initial attachment, while the monomeric pilins on the surface of the bacteria participate in the formation of an adhesion zone allowing the delivery of toxins and other virulence factors and may even play a significant role in host cell signaling ([@bib33]).

In addition to pili, *C. diphtheriae* produces the 67--72p protein located on its surface, which is involved in colonization, induction of apoptosis, and epithelial cell necrosis that were once attributed exclusively to the action of the diphtheria toxin ([@bib34]). This finding was also confirmed by [@bib4] who sequenced the genome of the British clinical isolate (strain NCTC13129 biotype *gravis* -- used in our study as the reference strain) and proved that the recent acquisition of pathogenicity factors went beyond the toxin itself and included the fimbrial proteins and adhesins. The 67--72p can act as an invasive and apoptotic protein for *C. diphtheriae* strains. The ability to penetrate, survive and induce apoptosis in epithelial cells may explain the endurance and dissemination of *C. diphtheriae* ([@bib34]). Proteins, which act as adhesins were also detected among other bacteria, e.g., the occurrence of the extracellular Eap protein was confirmed to be involved in colonization of eukaryotic cells by *S. aureus* strains ([@bib14]).

Our research is based on reverse vaccination. This method relies on the sequencing of pathogen genomes and determination *in silico* the most likely protective antigens prior to conducting experiments to prove this. Originally, this method was used to identify antigens as probable candidate vaccines against serogroup B meningococci ([@bib5]). In another study, [@bib9] used several available bioinformatics tools to design the efficient immunodominant epitopes for the development of the peptide vaccine against *C. pseudotuberculosis* for sheep and goats. Thanks to this research, it was possible to highlight the importance of bioinformatics software in the design of vaccines, especially in the identification of appropriate vaccine candidates, immune-informatics analysis and design of peptide vaccine from multi-epitopes ([@bib9]). Bioinformatics tools present a lot of advantages, such as speed and low cost, so we used them at particular stages of the research.

First, we selected the gene encoding the 67--72p protein and the three pili genes *spaC, sapD* and *spaI* as the genes most frequently detected in various *C. diphtheriae* isolates as it was reported in our previous study ([@bib48]). In the present study, we found two fragments of 594 bp and 215 bp in the nucleotide sequence of the gene coding for the 67--72p surface protein, which were identical in all analyzed strains of *C. diphtheriae*, and in total, nine identical in *C. diphtheriae* biotype *gravis* strains sequences of the genes encoding 67--72p protein and structural proteins pili SpaI, SpaC and SapD (Table [III](#tbl3){ref-type="table"}). The sequence stability of these fragments represents a first step toward being the potential vaccine candidates. The analysis of amino acid sequences of these fragments confirmed that the proteins tested are located in the membrane or cell wall and have a large extracellular part (Table [V](#tbl5){ref-type="table"}).

An effective vaccine should induce a protective and long-lasting immune response. Therefore, we carried out analyses of the affinity of the tested proteins to MHC classes I and II and linear B-cell epitopes. MHC class I presents antigens to CD8+ T-cells and MHC class II presents antigens to CD4+ T-cells. The antigens, which are recognized by CD4+ and/or CD8+ T-cell receptors, have the potential to stimulate a long-lasting and cytotoxic immune response. B-cell epitopes can induce both primary and secondary immunity. We showed that, in each of the proteins, areas with high affinity to MHC receptors can be distinguished (Table [VI](#tbl6){ref-type="table"}, Table [VII](#tbl7){ref-type="table"}, Table [VIII](#tbl8){ref-type="table"}) and we localized B-cell epitopes from target proteins (Table [IX](#tbl9){ref-type="table"}). In addition, the VaxiJen server was used that is a reliable and consistent tool for predicting protective antigens of bacterial, viral and cancer origin. The results obtained also confirmed that the proteins tested by us could be interesting to use as antigens in vaccines (Table [X](#tbl10){ref-type="table"}).

Our studies have shown that in the genome of the 89/E strain, the insertion element of 1380 bp was transposed and attached to fragment 4 of the gene encoding the SpaC pili protein. The process of transposition of ISs can inactivate genes ([@bib43]). [@bib21] confirmed the reduced *C. diphtheriae* adhesive activity as the result of mutations at the base pili protein SpaB and at the tip pili protein SpaC of the SpaA-type pili. Premature stop codons in the continuity of the genes encoding the proteins responsible for the adhesion of bacteria to host cells inactivate them and limit the colonization process. We did not investigate the adhesive activity of the strain 89/E and, therefore, we can only posit the influence of the insertion on the adhesive properties of the strain based on the data published by other researchers.

Due to the fact that in many European countries the number of infections with non-toxigenic *C. diphtheriae* strains has recently increased, a key aspect of our research was the understanding of virulence factors other than the diphtheria toxin and identification of new vaccine targets. An important problem is also the understanding of the colonization process and in particular the mechanism of adhesion and structure of the proteins, which participate in this process. Blocking the 67--72p surface protein or pili structural proteins could effectively prevent the adhesion of *C. diphtheriae* bacteria to host tissues, colonization, and infection development. Due to the comparison of the nucleotide sequences of the *C. diphtheriae* strains identification of the most conserved sequences in the genome and determination of the variability between strains was achieved. The conserved sequences identified in 67--72p, SpaC, SapD and SpaI in our study are identical for all *C. diphtheriae* strains tested and contain the epitopes for B-cells and T-cells and will be used in further research on the construction of a new vaccine. The main limitation of this study is the small number of isolates investigated. However, the results obtained here support further studies with a larger number of isolates from different countries. Moreover, the results of *in silico* analysis should be confirmed by *in vivo* studies on an animal model. The new vaccine will act to inactivate the antigens responsible for the host cell colonization by *C. diphtheriae* strains and inhibit the development of infection.
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